(firstQuint)Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia.

 This is a 7-week, Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group design study in male and female subjects with schizophrenia who are stabilised on antipsychotic medication.

 Subjects will be randomised to receive either GSK239512 or placebo for 7 weeks.

 They will undergo weekly review of safety, tolerability and cognitive performance measures.

.

 Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia@highlight

This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with schizophrenia